SCHEMBL4620729

SCHEMBL4620729

O=C(O)c1cc(NCc2ccsc2)n[nH]1

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.68
HCAR3 P49019 7/20 0.59
KDM4C Q9H3R0 1/20 0.49
NPC1 O15118 1/20 0.39
CA12 O43570 1/20 0.39
ALPL P05186 1/20 0.39
CA9 Q16790 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MAPK1 P28482 1/20 0.39
PTGS2 P35354 2/20 0.38
PNP P00491 1/20 0.38
TP53 P04637 1/20 0.38
GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4646927 0.75 KDM4C (0.52) HCAR2HCAR3KDM4CNPC1HDAC8
SCHEMBL15286846 0.66 KDM4C (1.00) KDM4C
Hydrochloric Acid SCHEMBL15286204 0.65 KDM4C (0.97) KDM4C
SCHEMBL18415486 0.65 GRM5 (0.53) KDM4CNPC1HDAC8HDAC6GRM5
SCHEMBL6720904 0.64 GRM5 (0.52) KDM4CNPC1HDAC8HDAC6GRM5
SCHEMBL28518683 0.64 HCAR3 (0.57) HCAR2HCAR3NPC1CA12ALPL
SCHEMBL28509025 0.64 CXCR4 (0.66) KDM4CNPC1TP53
SCHEMBL16763221 0.63 HCAR3 (0.50) HCAR2HCAR3CA12ALPLCA9
SCHEMBL9430237 0.62 GRM5 (0.50) KDM4CNPC1HDAC8HDAC6GRM5
SCHEMBL23942820 0.62 NPC1 (0.58) KDM4CNPC1CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899304-A1 5-AMINO-1H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE G-PROTEIN COUPLED RECEPTOR (GPCR) RUP38 FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF Arena Pharmaceuticals, Inc. (US) 2008-03-19 EP disclosed
WO-2006127595-A1 5-AMINOPYRAZOLE CARBOXYLIC ACID DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF ARENA PHARMACEUTICALS, INC. (US) 2006-11-30 WO disclosed